Baudax Bio, Inc.

Informe acción OTCPK:BXRX.Q

Capitalización de mercado: US$5.2k

Baudax Bio Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Baudax Bio's earnings have been declining at an average annual rate of -562.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 217.3% per year.

Información clave

-562.2%

Tasa de crecimiento de los beneficios

-118.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals 6.0%
Tasa de crecimiento de los ingresos217.3%
Rentabilidad financieran/a
Margen neto-4,665.2%
Última actualización de beneficios30 Sep 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Baudax Bio stock down after pricing $6.2M equity offering

Aug 30

Baudax Bio to get US patent linked to pain drug Anjeso

Aug 22

Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M

Aug 11

Cosette Pharmaceuticals appoints Rick Casten as CFO

Jul 06

Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds

Sep 09

A First Look At Baudax Bio

May 30

Baudax Bio EPS misses by $0.08, misses on revenue

May 05

Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty

Apr 26

Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Feb 17
Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Baudax Bio EPS of $0.62

Nov 09

Baudax Bio: Why I'm Catching This Falling Knife

Nov 03

Desglose de ingresos y gastos

Cómo gana y gasta dinero Baudax Bio. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

OTCPK:BXRX.Q Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Sep 231-59198
30 Jun 231-61187
31 Mar 231-58196
31 Dec 221-59244
30 Sep 22013243
30 Jun 2210323
31 Mar 221-11403
31 Dec 211-20453
30 Sep 211-66446
30 Jun 211-38477
31 Mar 211-53477
31 Dec 200-76439
30 Sep 200-66387
30 Jun 200-88298
31 Mar 200-692111
31 Dec 190-332317
30 Sep 190-422326
30 Jun 190-512334
31 Mar 190-613138
31 Dec 180-742936

Ingresos de calidad: BXRX.Q is currently unprofitable.

Margen de beneficios creciente: BXRX.Q is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Insufficient data to determine if BXRX.Q's year-on-year earnings growth rate was positive over the past 5 years.

Acelerando crecimiento: Unable to compare BXRX.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: BXRX.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rentabilidad financiera

Alta ROE: BXRX.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado